Hematopoetic

造血细胞移植与免疫重建研究计划(计划08) 重点阐述了造血细胞移植的基本生物学原理和 进一步治疗危及生命的恶性血液病患者。的主旋律 该计划是免疫学和干细胞生物学原理的发现，可以转化为 创新的基于红细胞压积的疗法。我们的目标是： ？对造血干细胞和祖细胞的细胞基础有基本的了解 嫁接。 探讨移植物抗宿主病(GVHD)和移植物抗肿瘤(GVT)的基础生物学 移植方面的反应。 ？制定改进免疫重建的策略。 ？将临床前研究中提出的有希望的概念转化为临床。 使用高度互动的研究小组和一系列丰富的动物模型 我们将在动物身上探索的细胞生物学、成像、遗传学和阵列技术的最新技术 模型和患者体内控制这些基于免疫的反应和发展的生物学原理 为我们的患者改善预后的策略。这些概念也可能对各种 其他临床情况，如自身免疫性疾病的治疗和固体诱导 器官移植耐受。使用翻译科学的原理，模型系统是 在实验室中开发，概念在临床中以双向方式进行测试，分析 患者的样本将使我们能够测试HCT的重要概念，并遵循在 研究实验室来治疗血液病患者。

The research program in Hematopoietic Cell Transplantation and Immune Reconstitution (Program 08) focuses on elucidating basic biological principles of hematopoietic cell transplantation (HCT) and furthering the treatment of patients with life-threatening hematologic malignancies. The major theme of the Program is the discovery of immunology and stem cell biology principles that can be translated into innovative HCT based therapies. Our goals are: ¿ To gain fundamental insights into the cellular basis of hematopoietic stem and progenitor cell engraftment. ¿ To explore the basic biology of graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) reactions in the context of transplantation. ¿ To develop strategies to improve immune reconstitution. ¿ To translate promising concepts developed in pre-clinical studies to the clinic. Using a highly interactive group of investigators with a rich array of animal models incorporating the latest techniques of cell biology, imaging, genetics and array technologies we will explore in animal models and in patients the biological principles that govern these immune-based reactions and develop strategies to improve outcomes for our patients. These concepts could also have an impact on a variety of other clinical situations, such as for the treatment of autoimmune disorders and induction of solid organ transplantation tolerance. Using the principles of translational science whereby model systems are developed in the laboratory and concepts are tested in the clinic in a bi-directional fashion, analyzing patients' samples will allow us to test important concepts of HCT and follow critical leads established in research laboratories to the treatment of patients with hematologic disorders.